Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 29

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 29
---
 OF PROXY AND E-MAIL OR MAIL THE ENTIRE PROXY PROMPTLY, IN ACCORDANCE WITH THE INFORMATION PROVIDED ON THE FRONT PAGE, IN ORDER TO ASSURE REPRESENTATION OF YOUR SHARES. IF THE FORM OF PROXY IS MAILED IN THE UNITED STATES IN THE ENCLOSED ENVELOPE, NO POSTAGE NEED BE AFFIXED. Date Signature Signature, if held jointly To change the address on your account, please check the box at right and indicate your new address. * SPECIMEN * REFERENCES TO ADDITIONAL INFORMATION This proxy statement/prospectus incorporates important business and financial information about NLS that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (the “SEC”) website ( www.sec.gov) or upon your written or oral request by contacting the Chief Executive Officer of NLS Pharmaceuticals Ltd., at The Circle6, 8058 Zurich, Switzerland, or by calling +41.44.512.2150. To facilitate timely delivery of these documents, any request should be made no later than , 2025 to receive them before theextraordinary meeting of shareholders of NLS (the “NLS Meeting”) . For additional details about where you can find information about NLS, please see the section entitled “ Where You Can Find More Information” in this proxy statement/prospectus. The contents of the websites of the SEC, NLS, Kadimastem, or any other entity are not being incorporated into this proxy statement/prospectus. The information about how you can obtain certain documents that are incorporated by reference into this proxy statement/prospectus at these websites is being provided only for your convenience. ABOUT THIS PROXY STATEMENT/PROSPECTUS This proxy statement/prospectus, which forms part of a registration statement on Form F -4filed with the SEC by NLS (File No. 333 -284075), constitutes a notice of meeting and proxy statement with respect to the NLS Meeting and a prospectus of NLS under Section 5 of the Securities Act of 1933, as amended, which is referred to as the Securities Act, with respect to the NLS Common Shares to be issued to Kadimastem shareholders pursuant to the Agreement and Plan of Merger, dated November 4, 2024, by and between NLS, NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd., which was further amended on January30, 2025 and February4